The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

Giovanni Tomasello, Antonella Marino Gammazza, Vincenzo Davide Palumbo, Attilio Ignazio Lo Monte, Giuseppe Damiano, Francesco Carini, Marcello Romeo, Salvatore Buscemi, Antonella Marino Gammazza, Alice Gerges-Geagea, Giovanni Tomasello, Vincenzo Davide Palumbo, Abdo Jurjus, Provvidenza Damiani

Risultato della ricerca: Article

13 Citazioni (Scopus)

Abstract

Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
Lingua originaleEnglish
pagine (da-a)372-377
Numero di pagine6
RivistaDefault journal
Volume160
Stato di pubblicazionePublished - 2016

Fingerprint

Probiotics
Ulcerative Colitis
Mesalamine
Lactobacillus acidophilus
Bifidobacterium
Inflammatory Bowel Diseases
Oral Administration
Anti-Inflammatory Agents
Therapeutics
Dysbiosis
Weapons
Pharmaceutical Preparations
Clinical Studies
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cita questo

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. / Tomasello, Giovanni; Marino Gammazza, Antonella; Palumbo, Vincenzo Davide; Lo Monte, Attilio Ignazio; Damiano, Giuseppe; Carini, Francesco; Romeo, Marcello; Buscemi, Salvatore; Gammazza, Antonella Marino; Gerges-Geagea, Alice; Tomasello, Giovanni; Palumbo, Vincenzo Davide; Jurjus, Abdo; Damiani, Provvidenza.

In: Default journal, Vol. 160, 2016, pag. 372-377.

Risultato della ricerca: Article

@article{5a332ad06e144b97914e0829a6928d30,
title = "The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study",
abstract = "Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.",
author = "Giovanni Tomasello and {Marino Gammazza}, Antonella and Palumbo, {Vincenzo Davide} and {Lo Monte}, {Attilio Ignazio} and Giuseppe Damiano and Francesco Carini and Marcello Romeo and Salvatore Buscemi and Gammazza, {Antonella Marino} and Alice Gerges-Geagea and Giovanni Tomasello and Palumbo, {Vincenzo Davide} and Abdo Jurjus and Provvidenza Damiani",
year = "2016",
language = "English",
volume = "160",
pages = "372--377",
journal = "Default journal",

}

TY - JOUR

T1 - The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

AU - Tomasello, Giovanni

AU - Marino Gammazza, Antonella

AU - Palumbo, Vincenzo Davide

AU - Lo Monte, Attilio Ignazio

AU - Damiano, Giuseppe

AU - Carini, Francesco

AU - Romeo, Marcello

AU - Buscemi, Salvatore

AU - Gammazza, Antonella Marino

AU - Gerges-Geagea, Alice

AU - Tomasello, Giovanni

AU - Palumbo, Vincenzo Davide

AU - Jurjus, Abdo

AU - Damiani, Provvidenza

PY - 2016

Y1 - 2016

N2 - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

AB - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

UR - http://hdl.handle.net/10447/202597

UR - http://biomed.papers.upol.cz/doi/10.5507/bp.2016.044.pdf

M3 - Article

VL - 160

SP - 372

EP - 377

JO - Default journal

JF - Default journal

ER -